Background: A wide variety of myelosuppressive chemotherapy regimens are used for the
treatment of cancer in clinical practice. Neutropenic complications, such as febrile …

Chemotherapy dose intensity represents unit dose of chemotherapy administered per unit
time. Dose intensity can be increased or decreased through altering dose administered, time …

Myelosuppression continues to represent the major dose-limiting toxicity of cancer
chemotherapy. Neutropenia and its complications, including febrile neutropenia, occur most …

This study was undertaken to describe the relationship between the occurrence and timing
of neutropenic events and chemotherapy treatment in a community-based population of …

Neutropenic complications remain an important dose‐limiting toxicity of cancer
chemotherapy‐associated with considerable morbidity, mortality, and cost. Risk of the initial …

Goals of work Neutropenia is a life-threatening, dose-limiting toxicity of many chemotherapy
regimens. The goals of this study were to assess the incidence and risk of chemotherapy …

Background The effects of chemotherapy dose intensity on patient outcomes in advanced
cancer are not well understood. We studied the association between chemotherapy relative …

Treatment-associated neutropenia continues to represent the most common dose-limiting
toxicity of cancer chemotherapy. It often leads to fever and infection, prompting …

Introduction: Myelosuppression represents the major dose-limiting toxicity of cancer
chemotherapy. This prospective, nationwide study was undertaken to better define risk of …

The ability to deliver the planned dose and intensity of chemotherapy (the amount of drug
administered/unit of time) is important for tumour control and survival. In clinical practice …